Nisa Investment Advisors
ACRS icon

Nisa Investment Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Nisa Investment Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Hold
318
– – ﹤0.01% 2778
2026
Q1 		$1.19K Hold
318
– – ﹤0.01% 2715
2025
Q4 		$957 Hold
318
– – ﹤0.01% 2717
2025
Q3 		$604 Hold
318
– – ﹤0.01% 2824
2025
Q2 		$452 Hold
318
– – ﹤0.01% 2888
2025
Q1 		$487 Hold
318
– – ﹤0.01% 2802
2024
Q4 		$789 Hold
318
– – ﹤0.01% 2727
2024
Q3 		$366 Sell
318
-209
-40% -$256 ﹤0.01% 2772
2024
Q2 		$580 Buy
+527
New +$619 ﹤0.01% 2652
2023
Q4 		– Sell
-1,067
Closed -$7.31K – 2640
2023
Q3 		$7.31K Sell
1,067
-2,182
-67% -$18.6K ﹤0.01% 2230
2023
Q2 		$33.7K Buy
3,249
+2,802
+627% +$25.4K ﹤0.01% 1891
2023
Q1 		$4K Sell
447
-1,434
-76% -$18.2K ﹤0.01% 2252
2022
Q4 		$30K Hold
1,881
– – ﹤0.01% 1931
2022
Q3 		$29K Buy
1,881
+53
+3% +$835 ﹤0.01% 1936
2022
Q2 		$26K Buy
+1,828
New +$25.6K ﹤0.01% 1962

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Nisa Investment Advisors's ACRS Position: Q2 2026 in Review

Nisa Investment Advisors held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 318 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2778.

Nisa Investment Advisors first reported a position in ACRS in Q2 2022 and has held it in 15 quarters since. The position peaked at $33.7K in Q2 2023. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Nisa Investment Advisors held 318 shares of Aclaris Therapeutics worth $1.68K as of Q2 2026.
  • Nisa Investment Advisors left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2778 holding.
  • Nisa Investment Advisors first reported a position in Aclaris Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Nisa Investment Advisors's Aclaris Therapeutics position peaked at $33.7K in Q2 2023.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.